March 29, 2024

News Collective

Complete New Zealand News World

Fresenius increased its turnover by 3% in 2021 to 37,520 million euros

Fresenius increased its turnover by 3% in 2021 to 37,520 million euros

Fresenius increases its sales in the year of the vaccine. The German group finished 2021 with a spin 37,520 million eurosWhich translates to a 3% increase compared to the results for 2020, according to the latest results published by the German group this Tuesday.

Earning before interest and taxes (ebit) was €4,158 million, down 5% from 2020, and net profit increased 8%, up to 1800 million euros. Of the company, Fresenius CEO Stefan Sturm explained, “Commercially, 2021 has been a challenging but successful year: we had a strong final quarter and fully met our targets for the year; in 2022 we expect continued profitable growth, despite higher rates Inflation and the ongoing burdens caused by the pandemic.”

The CEO adds that “in our Cost and Efficiency program, we have made faster than expected progress; this is an important factor that allows us to confirm the medium-term goals we set long before the outbreak of the pandemic, giving us more reason to look forward with optimism.”

Expenditure on property, plant and equipment in 2021 amounted to €2,032 million, representing 5% of sales. These investments served mainly in the modernization and expansion of dialysis clinics, production facilities, as well as hospitals and day clinics.

Spending on acquisitions in 2021 totaled €1,085 million, primarily for the purchase of Eugin, consolidated as of April 1, 2021, and the acquisition of Fresenius Medical Care’s dialysis clinics, according to the German group.

Eugin contributed 133 million euros to sales and 19 million euros to EBIT to the German group in 2021. Beginning in the first quarter of 2022, Eugin’s sales and EBIT will be published on a quarterly basis, Fresenius notes.

See also  US Dominates Crypto ATM Installations and BTC Hash Rate Worldwide By Cointelegraph

In 2021, The Group’s operating cash flow was 5,078 million, with a margin of 13.5%, compared to 6,549 million euros a year earlier. The decline was largely driven by Fresenius Medical Care due to US federal relief funds and payments made under the Coronavirus Aid, Relief and Economic Security Act.